A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies
- 2 March 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 379 (9818), 823-832
- https://doi.org/10.1016/S0140-6736(11)61941-7
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?JNCI Journal of the National Cancer Institute, 2010
- Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung CancerJournal of Clinical Oncology, 2010
- Prognostic gene signatures for non-small-cell lung cancerProceedings of the National Academy of Sciences of the United States of America, 2009
- Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study GroupsJournal of Clinical Oncology, 2008
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation studyNature Medicine, 2008
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung CancerPLoS Medicine, 2006
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002